Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Monoamine Oxidase B Inhibitors Versus Other Dopaminergic Agents in Early Parkinson's Disease." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/432847/all/Monoamine_oxidase_B_inhibitors_versus_other_dopaminergic_agents_in_early_Parkinson's_disease.
Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432847/all/Monoamine_oxidase_B_inhibitors_versus_other_dopaminergic_agents_in_early_Parkinson's_disease. Accessed December 9, 2024.
Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432847/all/Monoamine_oxidase_B_inhibitors_versus_other_dopaminergic_agents_in_early_Parkinson's_disease
Monoamine Oxidase B Inhibitors Versus Other Dopaminergic Agents in Early Parkinson's Disease [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 09]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/432847/all/Monoamine_oxidase_B_inhibitors_versus_other_dopaminergic_agents_in_early_Parkinson's_disease.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease
ID - 432847
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/432847/all/Monoamine_oxidase_B_inhibitors_versus_other_dopaminergic_agents_in_early_Parkinson's_disease
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -